13F Holdings
中文EN

NXGL NEXGEL, INC.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1468929 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY5.5%
TTM net income YoY-130.7%
TTM EPS YoY-45.3%
Revenue 3-yr CAGR51.6%
Net income 3-yr CAGR—

Margins

Gross margin33.4%
Operating margin-58.6%
Net margin-54.0%
FCF margin—
EBITDA margin-40.4%

Returns

ROE-142.7%
ROA-37.4%
ROIC (approx.)-153.8%
Asset turnover0.69x

Leverage & solvency

Liabilities / assets80.5%
Debt / equity0.00x
Current ratio0.46x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.53x
Accruals ratio-17.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$11.42M$8.69M$4.09M$2.05M$1.55M
Cost of revenue$6.91M$5.94M$3.71M$1.79M$1.54M
Gross profit$4.51M$2.75M$374,000$256,000$8,000
R&D expense$2,000$78,000$103,000$367,000$31,000
SG&A expense$7.86M$6.22M$3.75M$3.24M$2.55M
Operating income-$3.35M-$3.55M-$3.48M-$3.35M-$2.57M
Interest expense$34,000$81,000$15,000$1.34M—
Pretax income-$2.89M-$3.46M-$3.19M-$4.75M—
Income tax———$0$0
Net income-$3.00M-$3.28M-$3.16M-$4.75M-$4.31M
EBITDA-$2.90M-$3.12M-$3.25M-$3.24M-$2.46M
EPS (basic)-0.38-0.50-0.56-0.85-1.45
EPS (diluted)-0.38-0.50-0.56-0.85-1.45
Weighted avg. shares (diluted)7.85M6.51M5.67M5.57M2.98M
Balance sheet
Cash & equivalents$317,000$1.81M$2.70M$1.10M$13.35M
Short-term investments———$5.51M—
Receivables$673,000$933,000$633,000$222,000$209,000
Inventory$2.11M$1.75M$1.32M$502,000$291,000
Current assets$4.34M$5.11M$5.05M$7.50M$13.93M
PP&E, net$1.96M$2.21M$1.50M$721,000$723,000
Goodwill$1.13M$1.13M$1.13M$311,000$311,000
Intangibles$681,000$807,000$326,000$20,000$33,000
Total assets$10.46M$10.98M$9.96M$10.36M$16.98M
Current liabilities$2.96M$2.47M$2.55M$859,000$2.89M
Short-term debt——$245,000——
Long-term debt$588,000$685,000$593,000$283,000—
Total debt$588,000$685,000$838,000$283,000—
Total liabilities$5.57M$4.90M$4.79M$2.72M$4.90M
Shareholders' equity$4.46M$5.75M$4.70M$7.64M$12.09M
Net debt$271,000-$1.12M-$1.86M-$818,000—
Shares outstanding407,1577.64M5.74M5.58M5.57M
Cash flow statement
Operating cash flow-$1.31M-$3.87M-$3.24M-$2.99M-$2.75M
Capital expenditure$68,000$443,000$696,000$96,000$269,000
Free cash flow-$1.38M-$4.31M-$3.93M-$3.09M-$3.02M
Investing cash flow-$68,000-$775,000$4.46M-$5.59M-$269,000
Financing cash flow$630,000$3.75M$379,000-$3.66M$16.34M
Depreciation & amortization$450,000$436,000$226,000$112,000$113,000
Stock-based compensation$654,000$367,000$217,000$298,000$285,000

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.